Loading...
BCEL logo

Atreca, Inc.OTCPK:BCEL Stock Report

Market Cap US$3.6m
Share Price
n/a
My Fair Value
n/a
1Y-92.2%
7D0%
1D
Portfolio Value
​
View

Atreca, Inc.

OTCPK:BCEL Stock Report

Market Cap: US$3.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca (BCEL) Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. More details

BCEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Does not have a meaningful market cap ($4M)

Highly volatile share price over the past 3 months

+ 2 more risks

BCEL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Atreca, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Atreca
Historical stock prices
Current Share PriceUS$0.09
52 Week HighUS$1.18
52 Week LowUS$0.052
Beta1.03
1 Month Change-2.17%
3 Month Change-40.00%
1 Year Change-92.17%
3 Year Change-98.85%
5 Year Change-99.47%
Change since IPO-99.50%

Recent News & Updates

Recent updates

Analysis Article • Jul 23

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 08

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 08

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca press release (NASDAQ:BCEL): Q2 GAAP EPS of -$0.72 misses by $0.02. cash and cash equivalents and investments totaled $101.7 million.
Analysis Article • Jun 18

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 22

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients (66%) who took ATCR-101 with H-score ≥ 50 responded. Phase 1b study was updated to recruit higher expression solid tumor patients for ATRC-101, with additional monotherapy and combination data expected in 2nd half of 2022. ATRC-101 being expanded to target solid tumor types that express the gene EphA2; IND-enabling studies ongoing with IND filing expected 1st half of 2023. Atreca Inc. had $148.1 million in cash as of December 31, 2021, enough cash to fund its operations through the 1st half of 2023.
Analysis Article • Mar 05

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jan 25

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Atreca's share price performance has been abysmal over the past 12 months - the stock has lost >85% of its value. The biotech IPOd in June 2019, raising >$100m to fund development of drugs developed by studying the successful immune responses of patients. ATRC-101 targets various solid tumors and is in a Phase 1 trial - initial data has been underwhelming with some safety issues and only six partial responses in 20 solid. There are other preclinical assets and a development partnership with Xencor to co-develop two drugs, as well as a Malaria therapy being developed with the Bill and Melinda Gates Foundation. Atreca stock may have punished too severely in my view and I can see an upside opportunity here - although drug development is a hit and miss industry, I see the risk reward here as potentially attractive for those with an appetite.
Seeking Alpha • Sep 10

Atreca: Safety Data Brought Down Stock

BCEL has very high smart money involvement. Poor adverse event data brought the stock down in July. The pipeline is in very early stage.
Analysis Article • Sep 02

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 14

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 29

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Analysis Article • Dec 07

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

BCELUS BiotechsUS Market
7D0%-2.4%0.3%
1Y-92.2%28.3%26.2%

Return vs Industry: BCEL underperformed the US Biotechs industry which returned 5.5% over the past year.

Return vs Market: BCEL underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is BCEL's price volatile compared to industry and market?
BCEL volatility
BCEL Average Weekly Movement21.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BCEL's share price has been volatile over the past 3 months.

Volatility Over Time: BCEL's weekly volatility has decreased from 29% to 21% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201090John Orwinwww.atreca.com

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.

Atreca, Inc. Fundamentals Summary

How do Atreca's earnings and revenue compare to its market cap?
BCEL fundamental statistics
Market capUS$3.57m
Earnings (TTM)-US$97.76m
Revenue (TTM)n/a
0.0x
P/S Ratio
0.0x
P/E Ratio

Is BCEL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BCEL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$97.76m
Earnings-US$97.76m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BCEL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/16 11:57
End of Day Share Price 2024/06/14 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atreca, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Kumaraguru RajaBrookline Capital Markets
John NewmanCanaccord Genuity